Synthaverse S.A. Cash Flow Conversion Efficiency

Latest as of March 2025: 0.072x

Synthaverse S.A. cash flow conversion efficiency. Based on the latest financial reports, Synthaverse S.A. (SVE) has a cash flow conversion efficiency ratio of 0.072x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł8.68 Million ≈ $2.39 Million USD) by net assets (zł120.93 Million ≈ $33.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Synthaverse S.A. (2010–2024)

Cash flow conversion efficiency of Synthaverse S.A. from 2010 to 2024. This chart illustrates how Synthaverse S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Synthaverse S.A. share price for real-time trading data and today's change.

Synthaverse S.A. Cash Flow Conversion Ratio Explained

Synthaverse S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Synthaverse S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Synthaverse S.A. ranked by their cash flow conversion efficiency. Also see SVE company net worth for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Supremex Inc.
TO:SXP
0.039x
Xin Chio Global Co Ltd
TWO:3171
0.084x
Broad Capital Acquisition Corp
NASDAQ:BRAC
0.008x
Saehwa IMC Co Ltd
KO:145210
0.026x
ADOLFO DOMINGUEZ
MC:ADZ
0.253x
An Gia Real Estate Investment and Development Corp
VN:AGG
-0.015x
Reitmans (Canada) Limited
V:RET-A
0.214x
Hil Industries Bhd
KLSE:8443
-0.027x

Annual Cash Flow Conversion Efficiency for Synthaverse S.A. (2010–2024)

The table below shows the annual cash flow conversion efficiency of Synthaverse S.A. from 2010 to 2024. Review SVE cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 zł121.47 Million
≈ $33.43 Million
zł13.73 Million
≈ $3.78 Million
0.113x +338.13%
2023-12-31 zł112.64 Million
≈ $31.00 Million
zł-5.34 Million
≈ $-1.47 Million
-0.047x -269.91%
2022-12-31 zł105.56 Million
≈ $29.05 Million
zł2.95 Million
≈ $811.33K
0.028x +163.46%
2021-12-31 zł74.55 Million
≈ $20.52 Million
zł-3.28 Million
≈ $-902.98K
-0.044x -578.66%
2020-12-31 zł37.31 Million
≈ $10.27 Million
zł343.00K
≈ $94.40K
0.009x -96.30%
2019-12-31 zł32.87 Million
≈ $9.05 Million
zł8.16 Million
≈ $2.25 Million
0.248x +1317.34%
2018-12-31 zł30.40 Million
≈ $8.37 Million
zł-620.00K
≈ $-170.63K
-0.020x -127.07%
2017-12-31 zł57.81 Million
≈ $15.91 Million
zł4.36 Million
≈ $1.20 Million
0.075x -99.46%
2016-12-31 zł1.13 Million
≈ $310.17K
zł15.77 Million
≈ $4.34 Million
13.993x +9585.14%
2015-12-31 zł20.00 Million
≈ $5.51 Million
zł-2.95 Million
≈ $-812.18K
-0.148x -566.59%
2014-12-31 zł57.25 Million
≈ $15.76 Million
zł-1.27 Million
≈ $-348.68K
-0.022x +81.02%
2013-12-31 zł58.49 Million
≈ $16.10 Million
zł-6.82 Million
≈ $-1.88 Million
-0.117x +37.91%
2012-12-31 zł44.75 Million
≈ $12.32 Million
zł-8.40 Million
≈ $-2.31 Million
-0.188x +42.69%
2011-12-31 zł50.06 Million
≈ $13.78 Million
zł-16.41 Million
≈ $-4.51 Million
-0.328x -268.73%
2010-12-31 zł14.06 Million
≈ $3.87 Million
zł-1.25 Million
≈ $-343.86K
-0.089x --

About Synthaverse S.A.

WAR:SVE Poland Biotechnology
Market Cap
$55.05 Million
zł200.03 Million PLN
Market Cap Rank
#21351 Global
#189 in Poland
Share Price
zł2.64
Change (1 day)
-0.38%
52-Week Range
zł2.64 - zł4.19
All Time High
zł30.00
About

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 5… Read more